Last updated: June 3, 2026
Why peptides are cycled
Most therapeutic peptide cycles exist for three reasons:
- Receptor desensitization: Some receptors downregulate with continuous high-dose stimulation. GHRP receptors (especially hexarelin) can desensitize.
- HPG/HPA axis disruption: Continuous exogenous hormone activity can suppress endogenous production. Resting allows the natural axis to recover.
- Cost and complexity: Cycling reduces total annual exposure and cost.
Standard cycle durations by class
| Peptide class | Cycle on | Cycle off | Rationale |
|---|---|---|---|
| GHRP (Ipamorelin, GHRP-2) | 8-12 weeks | 4-6 weeks | Prevent receptor desensitization |
| GHRH (Sermorelin, CJC-1295) | 8-12 weeks | 4-6 weeks | Align with GHRP cycling |
| Tissue repair (BPC-157, TB-500) | 4-8 weeks | 4-8 weeks | Match acute injury healing timeline |
| IGF-1 LR3 | 4-6 weeks | 4-6 weeks | Limit IGF-1 elevation to prevent receptor downregulation |
| Longevity (Epitalon, Thymalin) | 10-20 days | 3-12 months | Khavinson protocol — pulse dosing 1-4x yearly |
| GLP-1 (Semaglutide, Tirzepatide) | Continuous | None (long-term) | Weight regain occurs with discontinuation |
| Cognitive (Selank, Semax) | 2-4 weeks | 2-4 weeks | Short courses, prevent tolerance |
What “rest periods” actually do
During cycle-off periods:
- Receptor density returns to baseline
- HPG and HPA axes recover
- Endogenous GH pulsatility normalizes (after GHRP cycles)
- Lab values (IGF-1, fasting insulin) return toward baseline
Peptides that don’t need cycling
Some peptides work continuously without significant downregulation:
- GLP-1 receptor agonists: Continuous use is the standard. Discontinuation causes weight regain.
- GHK-Cu topical: No tolerance development; can be used daily long-term.
- Some cosmetic peptides: Local skin application doesn’t have systemic feedback issues.
Cycling and lab monitoring
Useful labs to track during cycles:
- Baseline (pre-cycle): Full panel including IGF-1, fasting insulin, A1C, lipid panel, CBC, CMP
- Mid-cycle (week 6-8): IGF-1 (to gauge GH response), fasting insulin
- End-of-cycle: Repeat full panel
- Post-rest (before next cycle): IGF-1 and fasting insulin should return toward baseline
Common cycling mistakes
- Cycling drugs that don’t need it (like GLP-1s, which require continuous use for effect)
- Rest periods too short — receptor recovery is gradual
- Not monitoring labs — chronically elevated IGF-1 or insulin can indicate inadequate rest
- Switching peptides during the rest period — defeats the purpose of resting the endocrine axis
Why don’t all peptides need cycling?<br />
Some peptides target receptors that don’t desensitize (GLP-1R is famously resistant to tachyphylaxis). Others act on pathways that don’t trigger negative feedback (cosmetic topicals).
Can I extend a peptide cycle past 12 weeks?<br />
For GHRPs and IGF-1 analogs, extended cycles increase risk of receptor desensitization and HPA axis suppression. For other classes, extended use may be appropriate — depends on the specific peptide.
What if I miss a dose during a cycle?<br />
One missed dose is rarely consequential. Resume the schedule with the next planned dose; don’t double up.
Can I cycle different peptides in alternating cycles?<br />
Yes — common to alternate “growth” cycles (CJC-1295/Ipamorelin) with “recovery” cycles (BPC-157/TB-500), with brief rest periods between.
Related guides: Peptide stacks guide · How to measure peptide doses · Peptide protocols